2
2
2018
2018
Company (2)University (1)
1 - 2 of 2
Sort by
Clinical Trial
Clinical Trial IDNCT03385486Start Date2018-05-01Completion Date2022-04-01PhasePhase 1Study TypeInterventionalStatusNot yet recruiting
This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors. The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.
Clinical Trial
Clinical Trial IDNCT02860559Start Date2018-04-01Completion Date2022-03-01PhasePhase 1Study TypeInterventionalStatusNot yet recruiting
This is a study of stem cell transplantation with TBX-1400 in pediatric subjects with severe combined immunodeficiency (SCID). The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way. This study has two goals. The first goal is to find out if transplant with TBX-1400 is safe. The second g…
We found 2 documents that match your Search
Research Grants: 8
Patents: 89
Clinical Trials: 2
SEC Filings: 3

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in